The clinical trials market is witnessing strong momentum as pharmaceutical and biotechnology companies continue to increase investments in research and development to accelerate the discovery of advanced therapies. The global clinical trials market size was estimated at USD 89.0 billion in 2025 and is projected to reach USD 158.4 billion by 2033, growing at a CAGR of 7.7% from 2026 to 2033. The market expansion is being fueled by the growing prevalence of chronic and rare diseases, increasing adoption of precision medicine, and rapid advancements in biotechnology. Clinical trials have become a crucial component in the development of innovative drugs, biologics, and targeted therapies, especially for conditions with unmet medical needs. In addition, the growing use of digital technologies and data-driven approaches is transforming trial management, enabling improved patient recruitment, real-time monitoring, and enhanced operational efficiency across studies.

Another major factor contributing to market growth is the increasing shift toward decentralized and virtual clinical trials, which are improving accessibility and patient participation rates worldwide. Pharmaceutical companies are increasingly outsourcing clinical trial services to specialized contract research organizations (CROs) to reduce operational complexities and accelerate drug development timelines. The rising incidence of diseases such as cancer, diabetes, cardiovascular disorders, and neurological conditions continues to create substantial demand for innovative therapies and advanced treatment options. Furthermore, supportive regulatory frameworks and expanding collaborations between biotechnology firms and pharmaceutical giants are strengthening the competitive landscape. Strategic partnerships and acquisitions are also enabling companies to enhance their research capabilities and expand their global clinical trial networks.

Download a free sample copy of the Clinical Trials market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

·         The North America clinical trials market held the largest global share of 50.7% in 2025. The region continues to dominate due to the presence of leading pharmaceutical companies, advanced healthcare infrastructure, strong regulatory support, and high investments in clinical research activities. The U.S. clinical trials industry is expected to grow lucratively from 2026 to 2033, supported by increasing drug development programs and growing adoption of decentralized clinical trial models.

·         By phase, the phase III segment held the largest market share of 53.6% in 2025. Phase III trials remain highly significant as they involve large patient populations and play a critical role in evaluating the safety and effectiveness of new therapies before regulatory approval. Increasing investments in late-stage drug development are expected to further support the segment’s growth.

·         By study design, the interventional trials segment held the largest market share in 2025. Interventional studies are widely utilized in evaluating new drugs, medical devices, biologics, and treatment procedures, making them a key component of the overall clinical trials landscape.

·         By indication, the oncology segment held the largest revenue share in 2025. The growing burden of cancer worldwide, along with the rapid development of immunotherapies, targeted therapies, and personalized medicine solutions, continues to drive clinical trial activity in oncology research.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

The competitive landscape of the clinical trials market is highly dynamic, with leading companies focusing on mergers & acquisitions, partnerships, service launches, and geographic expansions to strengthen their market position. Key players operating across the market are adopting strategic initiatives to gain a competitive edge. For instance, in February 2025, Summit Therapeutics Inc. announced a collaboration with Pfizer Inc. to conduct a clinical trial evaluating ivonescimab, an innovative investigational PD-1/VEGF bispecific antibody. This study will explore the use of ivonescimab in combination with various antibody drug conjugates (ADCs) developed by Pfizer, targeting multiple solid tumor indications.

Key Clinical Trials Companies:

·        IQVIA Inc.

·        Parexel International Corporation

·        Thermo Fisher Scientific Inc.

·        ICON Plc.

·        LabCorp

·        Syneos Health

·        Novotech

·        Avance Clinical

·        George Clinical

·        Veritus Research

·        Eli Lilly and Company

·        F. Hoffmann-La Roche Ltd.

·        Novo Nordisk A/S

·        Pfizer, Inc.

·        Actinogen Medical

·        Telix Pharmaceuticals

·        PYC Therapeutics

·        Neuren Pharmaceuticals

·        AbbVie

·        Merck Sharp & Dohme LLC

Explore Grand View Horizon to see global and regional level statistics related to the Clinical Trials Market

Grand View Research offers

·         Focused market intelligence reports on specific geographies or high-growth segments.

·         Extended forecast timelines for long-term planning.

·         Competitor Benchmarking and Supply Chain Analysis

·         Inclusion of regulatory and policy assessments.

·         Inclusion of custom data models, KPIs, or applications unique to your business

·         Specific high-impact Data Decks and Tables to support effective decision making

·         And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering